Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Deerfield Management to Acquire Singular Genomics for $20 Per Share in All-Cash Deal

EU Approval of Tagrisso Sets New Standard for EGFR-Mutated NSCLC Treatment

Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

Home
/
update
/
details

Pfizer Showcases Advancements in Hematology and Breast Cancer at ASH and SABCS 2023

NextEdge Admin

07 Dec 2024

2 min 42 sec

Pfizer Inc. is set to present significant advancements in hematology and breast cancer research at two major events: the American Society of Hematology (ASH) Annual Meeting (December 7–10) and the San Antonio Breast Cancer Symposium (SABCS, December 10–13). Across more than 100 abstracts, including 13 oral presentations and four poster spotlights, Pfizer will showcase its approved therapies and innovative pipeline for blood and breast cancers, along with rare blood disorders.

At ASH, Pfizer will highlight over 75 studies. Key updates include:

ADCETRIS® (brentuximab vedotin): Analyses from the pivotal ECHELON-3 trial emphasize its survival benefits in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and efficacy in elderly or heavily pretreated patients. Promising early-stage data in Hodgkin lymphoma will also be presented.
ELREXFIO® (elranatamab-bcmm): Data from the MagnetisMM-3 and MagnetisMM-20 trials reveal durable responses in relapsed/refractory multiple myeloma (RRMM), even with reduced dosing frequency.
SEA-CD70: Early results in high-risk myelodysplastic syndromes demonstrate the potential of this CD70-targeting antibody in enhancing outcomes in myeloid malignancies.

At SABCS, 30 studies, including real-world analyses of IBRANCE® (palbociclib), reaffirm its role in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (MBC). Highlights include:

Vepdegestrant: Phase 1b data suggest its potential as a new backbone endocrine therapy in ER+/HER2- MBC.
Atirmociclib: Emerging as a selective CDK4 inhibitor, early-phase studies show promise as a first-line therapy for HR+/HER2- MBC.
KAT6 inhibitor (PF-07248144): Results from heavily pretreated patients underline its role as a novel approach, with Phase 3 studies planned.

These findings reinforce Pfizer’s commitment to developing groundbreaking therapies and advancing care standards for patients with hematologic and breast cancers.